InventisBio Co., Ltd.

New Capabilities

Developer of nomelcitinib (D-2570)

InventisBio reported on Nov. 2, 2026 that its oral drug nomelcitinib met the main and secondary goals of a 391-patient Phase III trial in moderate-to-severe plaque psoriasis. More than 70% of patients on either of two doses reached PASI 90 at week 16, meaning their psoriasis severity score fell at least 90% from baseline. More than 80% reached a physician rating of clear or almost clear.

Updated 2 hours ago